Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: How about some news this week?

"If the decision was made within PDS not to distribute the money from the Feb patents, I think that's a good question since CJ is on that board. "

The recognition of income from PDS is not connected to when they distribute it. In simple terms, when PDS recognizes the income, so does PTSC.

" Our revenue amounts do not include income of approximately $11,657,000 from our investment in PDS for the three months ended February 28, 2007, or income of approximately $11,696,000 from our investment in PDS for the three months ended February 29, 2008. "

You are misinterpreting this. It is not saying that the revenue was not included in the overall income statement. It is pointing out that the income from PDS is not included in the Revenue line. Instead it is included in "Other Income" down below.

IMO if there is any "shifting" of income being done, it is thru the signing of the license agreements - in other words, announce a license in February, but not have it formally signed until March. At this point, again IMO, that is the most likely explanation of not having the February licenses announced included in the latest 10q ( if that is in fact the case)



Share
New Message
Please login to post a reply